Cargando…

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer

SIMPLE SUMMARY: This review summarizes reports from the latest clinical trials assessing the safety and clinical effectiveness of new biological drugs stimulating the immune system to fight cancer. The aim of this study is to show the enormous therapeutic potential of monoclonal antibodies in the tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wesolowski, Jakub, Tankiewicz-Kwedlo, Anna, Pawlak, Dariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406094/ https://www.ncbi.nlm.nih.gov/pubmed/36010854 http://dx.doi.org/10.3390/cancers14163860

Ejemplares similares

Kynurenines as a Novel Target for the Treatment of Malignancies
por: Mor, Adrian, et al.
Publicado: (2021)

Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders
por: Mor, Adrian, et al.
Publicado: (2021)

Crosstalk between Tryptophan Metabolism via Kynurenine Pathway and Carbohydrate Metabolism in the Context of Cardio-Metabolic Risk—Review
por: Kiluk, Małgorzata, et al.
Publicado: (2021)

Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer
por: Tankiewicz-Kwedlo, Anna, et al.
Publicado: (2018)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Simultaneous use of erythropoietin and LFM‐A13 as a new therapeutic approach for colorectal cancer
por: Tankiewicz‐Kwedlo, Anna, et al.
Publicado: (2018)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
por: Rozkiewicz, Dariusz, et al.
Publicado: (2020)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
por: Tong, Ling, et al.
Publicado: (2023)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Neurobehavioral effects of uremic toxin–indoxyl sulfate in the rat model
por: Karbowska, Malgorzata, et al.
Publicado: (2020)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
por: Llinàs-Arias, Pere, et al.
Publicado: (2021)

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2023)

Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts
por: Tankiewicz-Kwedlo, A., et al.
Publicado: (2016)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
por: Kudelova, Eva, et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
por: Li, Liying, et al.
Publicado: (2023)

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
por: Yang, Ruoning, et al.
Publicado: (2022)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review
por: K Patel, Khushbu, et al.
Publicado: (2022)

Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

The advance of adjuvant treatment for triple-negative breast cancer
por: Ge, Jingyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3d7ssjhps9asq8gm58vpb0fgp